EUCTR2021-001172-41-FI进行中（未招募）1 期
An Open-label, Multicenter Trial to Assess the Safety and Tolerability of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive Disorder
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 760
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Each patient entering the Open-label Safety Study must meet all of the following criteria:
- •1. In the opinion of the Investigator, the patient must have safely completed the lead-in study.
- •2. The patient must understand the written informed consent for the Open-label Safety Study, provide signed and witnessed written informed consent.
- •3. The patient is taking his/her ADT as prescribed from the lead-in study.
- •4. The patient must agree to continue using highly effective methods of birth control as specified in the lead-in study through the Safety-Follow-up Period of the Open-label Safety Study, or female patients or female partners of male patients must be of non-childbearing potential.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 755
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •Because all patients enrolled in the lead-in study were required to satisfy exclusion criteria for participation in the lead-in study, the Investigator should assess if there has been any change in patient health status. Any newly-emergent medical condition reported during the lead-in study must be evaluated by the Investigator and should be discussed with the Sponsor or designee before enrolling the patient in the study.
- •Patients enrolling directly from the lead-in study to the Open-label Safety Study at the Screening/Baseline Visit (Visit 1/Day 1) will be excluded if they meet the following criteria:
- •1. In the opinion of the Investigator, the patient is unable to comply with study procedures or judged to be inappropriate for the study.
- •2. In the opinion of the Investigator, the patient has a significant risk for suicidal behavior during the course of her/his participation in the study or is considered to be an imminent danger to her/himself or others, and/or:
- •a. At Visit 1/Day 1, the patient scores yes” on Suicidal Ideation Items 4 or 5 of the C-SSRS Since Last Visit” version;
- •b. At Visit 1/Day 1, the patient scores = 5 on the MADRS Item 10 (Suicidal Thoughts).
- •3. Based on the Investigator’s clinical judgement, any abnormal clinical laboratory test or ECG results obtained throughout the lead-in study that are considered clinically significant and preclude safe participation in the study.
- •4. The patient is breast-feeding or pregnant; female patients of childbearing potential must have a negative urine pregnancy test at Visit 1/Day 1.
- •5. Has a positive urine drug test at Visit 1/Day 1. Positive tests attributable to prescription treatments (eg, opioids, benzodiazepines) may not be exclusionary if the use is not chronic and is able to be safely discontinued based on Investigator judgment and with the concurrence of the Sponsor or designee.
- •6. The patient has any other condition that may be detrimental to the patient if she/he participates in the study.
研究者
相似试验
招募中
3 期
A study to estimate the Safety and acceptability of Lumateperone as another treatment used together with the primary treatment in the Treatment of Patients with Major Depressive DisorderCTRI/2023/04/052094Intra-Cellular Therapies, Inc.
进行中（未招募）
1 期
A Study to Assess the Safety and Tolerability of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive DisorderMajor Depressive DisorderEUCTR2021-001172-41-BGIntra-Cellular Therapies, Inc.760
进行中（未招募）
1 期
A Study to Assess the Safety and Tolerability of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive DisorderMajor Depressive DisorderEUCTR2021-001172-41-SKIntra-Cellular Therapies, Inc.760
进行中（未招募）
1 期
A Study to Assess the Safety and Tolerability of Lumateperone as Adjunctive Therapy in the Treatment of Patients with Major Depressive DisorderMajor Depressive DisorderEUCTR2021-001172-41-PLIntra-Cellular Therapies, Inc.760
已完成
不适用
An Open-label, Multicenter Study to Assess the Safety, Pharmacokinetics and Pharmacodynamic Effects of THB001 in Adult Patients with Chronic Cold UrticariaCold hives10001708Cold urticariaNL-OMON51543Third Harmonic Inc.11